As reported previously [40], tipifarnib was highly active in the HRAS mutant setting and displayed weak activity in the majority of HRAS wild-type models, but we observed unexpectedly robust inhibition of tumor growth in a minority of HRAS wild-type cases, all of which expressed high levels of the HRAS gene (Figure 2). Here, HRAS is linked to neoplasm.